Glycostem Therapeutics

A big day for Amanda van Vliet and Glycostem! It was great to see Amanda's development to become an excellent scientist and colleague over the years. Today, we are excited to join and support Amanda for her #phd defense on #NKcell #immunotherapy We are proud of you! You can follow Amanda's journey: "On the TRAIL of a killer: Mechanisms of action of an #allogeneic #NKcell #therapy" Live link: https://lnkd.in/eNMmiGbE

This week: we will showcase our latest developments including data on targeting #autoimmune diseases at #BioEurope in #Stockholm and at #Cell2024 in #London Adil Doganay Duru And Roel Schaapveld will represent Glycostem Therapeutics at the #BioEurope and will have over 20 meetings with potential #investors and #collaborators Monica Raimo and Volker Huppert will attend the #Cell2024 and will be: 1) Participating to a panel discussion on "#Cryopreservation Techniques & Transportation: Safeguarding Cell #Viability In #ATMP Development" 2) Presenting about "#NaturalKiller Cell Product Development As Non-Engineered, Engineered, And #CombinationTherapy" 3) Participating to a panel discussion on "Advancing Cell Therapies: Exploring Quality Control & Personalised Medicine Integration" For more info: https://lnkd.in/ezPCvX2z Stay tuned with us, we will have more updates in November!

- Superior Natural Killers - Learn the secrets of superior stem cell-derived, Natural Killer cell therapeutics. Glycostem's Dr. Amanda van Vliet and colleagues unravelled key distinctive traits of superior allogeneic NK cells. By integrating functional anti-tumor cytotoxicity, phenotypical, and molecular bulk and single cell RNA-Seq analysis, they identified a multi-factorial gene expression signature supporting the development of more efficacious NK therapies, now published in Molecular Therapy Oncology https://lnkd.in/eyuAwm4Q

We are excited to announce, that Amanda van Vliet will present at #CIMT2024 about our NK cell therapy and their multimodality to fight multiple cancers either alone, in combination or specific modifications. Please meet Amanda at 15th May in Mainz, joined by Anna-Maria Georgoudaki. The presentation is titled "Synergistic multimodal innate and antigen-specific activation mechanisms of hematopoietic stem cell-derived NK cells potentiate superior and sustained anti-tumor efficacy" and will be presented during poster session 1 with poster number 47 at #CIMT.

#innatekillersummit 2023 was a great meeting, especially with the pre-conference day setting the stage for the heavy next few days. I am looking forward to see the experts in the field, exciting #celltherapy talks and friends again at the #innatekillersummit 2024. As Jan Spanholtz mentioned below, we will be talking about #feederfree #NKcell expansion as well as #antigen specific targeting of #tumor cells via #ADCC, #CAR and #TCR Monday, we start with Anna-Maria Georgoudaki and me. Download the full agenda for more details: https://lnkd.in/e3pgirYj

Excited to talk at the 9th Innate Killer Summit in San Diego next week on the 18th and to join an exciting meeting with lots of interesting research and networking together with Adil Doganay Duru and Jan Spanholtz #NKcells #cancerimmunotherapy Glycostem Therapeutics

Ready to meet you next week at Innate Killer Summit 2024 March 18-20 in San Diego. I will present about Glycostem Therapeutics progress in the session "Investigating the Benefits of Feeder-Free NK Cell Expansion" and leading a panel discussion about "Setting the Gold Standard for Sourcing NK Cells for Scalable Protocols". I will be joined by Anna-Maria Georgoudaki and Adil Doganay Duru who will update on #ADCC and #CAR-NK and #TCR-NK in the bootcamp! #celltherapy #innatekillersummit

And the story continues ... showing our NK cells' influence to modulate the TME immune compartment. Check out our latest publication at Clinical & Experimental Immunology: “#Allogeneic #NK cells induce the in vitro activation of monocyte-derived and conventional type-2 #dendritic cells and trigger an #inflammatory response under cancer-associated conditions”. We showed that besides their direct cytolytic anti-tumor effect, #oNKord cells have the potential to induce activation of other immune cells, even under immunosuppressive conditions. A big thanks to all authors for their contribution to this work Elisa Toffoli, Amanda van Vliet, Caitlyn Forbes, Annemijn Arns, @Henk Verheul, Tuynman Jb, Hans van der Vliet, Jan Spanholtz, Tanja de Gruijl and our collaborators from Anthony Nolan Sarah Dean #NKcell #celltherapy, #immunotherapy, #oNKord https://lnkd.in/enp5QSaT

And the story continues ... showing our NK cells' influence to modulate the TME immune compartment. Check out our latest publication at Clinical & Experimental Immunology: “#Allogeneic #NK cells induce the in vitro activation of monocyte-derived and conventional type-2 #dendritic cells and trigger an #inflammatory response under cancer-associated conditions”. We showed that besides their direct cytolytic anti-tumor effect, #oNKord cells have the potential to induce activation of other immune cells, even under immunosuppressive conditions. A big thanks to all authors for their contribution to this work Elisa Toffoli, Amanda van Vliet, Caitlyn Forbes, Annemijn Arns, @Henk Verheul, Tuynman Jb, Hans van der Vliet, Jan Spanholtz, Tanja de Gruijl and our collaborators from Anthony Nolan Sarah Dean #NKcell #celltherapy, #immunotherapy, #oNKord https://lnkd.in/enp5QSaT

Qualified potency test for NK cell products! We are happy to announce that our latest article "Qualification of a flow cytometry-based method for for the evaluation of in vitro cytotoxicity of GTA002 natural killer cell therapy", resulting from a collaboration of Glycostem's R&D and quality departments, lead by Monica Raimo, has been published in Heliyon. We hope our work will support and stimulate cell therapy developers in developing assays for qualification and validation procedures, to assess the high functionality of their products; like we are doing for inaleucel. Happy reading! #NKcells #celltherapy #inaleucel #potencymethod https://lnkd.in/ew_JNmQN